Orexigen Therapeutics reported that all three remaining Phase III trials of Contrave, a combo of bupropion SR (a.k.a. Wellbutrin) and naltrexone SR, met their co-primary endpoints for the treatment of obesity. The results from the successfully completed Contrave Obesity Research, or COR, program of more than 4,500 patients exceed the FDA categorical efficacy benchmark for clinically significant weight loss, supporting the company’s plan to file an NDA with the FDA in the first half of 2010...